This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ip, S.
Right arrow Articles by O’Brien, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ip, S.
Right arrow Articles by O’Brien, R.
Related Collections
Right arrow Office Practice
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
PEDIATRICS Vol. 114 No. 1 July 2004, pp. 263-264


COMMENTARY

Hyperbilirubinemia and Kernicterus: 50 Years Later

Stanley Ip, MD*, Joseph Lau, MD{ddagger}, Mei Chung, MPH{ddagger}, John Kulig, MD*, Robert Sege, MD*, Stephan Glicken, MD* and Rebecca O’Brien, MD*

* Department of Pediatrics
{ddagger} Tufts-New England Medical Center Evidence-Based Practice Center,
Tufts-New England Medical Center,
Boston, MA 02111

Abbreviations: TSB, total serum bilirubin

In 1952, Hsia et al1 reported that 50% of infants with erythroblastosis fetalis in whom the total serum bilirubin (TSB) was >30 mg/dL developed kernicterus. The authors further reported that kernicterus did not occur in >200 consecutive cases of erythroblastosis fetalis when the hospital policy was to keep the serum bilirubin level <20 mg/dL. They concluded that "although it has not been proved that bilirubin is the actual cause of brain damage, tests of serum bilirubin in infants with erythroblastosis fetalis serve as extremely valuable guides to treatment."

There is no doubt that bilirubin plays a major role in the development of central nervous system pathology. High-quality studies27 have consistently demonstrated abnormal brainstem auditory evoked responses to elevated serum bilirubin levels. Indirect evidence from the decreasing prevalence of kernicterus since the introduction of Rhogam and prophylactic use of phototherapy also implicates hyperbilirubinemia as a major factor associated with kernicterus. However, >50 years after the report by Hsia et al, the premise that hyperbilirubinemia alone is sufficient to explain kernicterus is still not entirely satisfactory.

In our review of 123 cases of kernicterus in infants ≥34 weeks’ gestation published between 1955 and 2001, 88 had comorbid factors such as hemolysis, sepsis, and other neonatal complications.8 It was not possible to separate the effects of these comorbid factors from hyperbilirubinemia to further elucidate the chain of events leading to kernicterus. We concluded that hyperbilirubinemia, in most cases, is a necessary but not sufficient condition to explain kernicterus. Epidemiologic studies are useful to evaluate factors associated with disease outcome, but they offer inadequate proof for causation.

Additional understanding of bilirubin neurotoxicity is clearly needed and may be forthcoming from basic science investigations. Ostrow et al9 have proffered new concepts in bilirubin pathophysiology based on studies of bilirubin toxicity in cultured cells from the central nervous system and in jaundiced Gunn rats and measurement of the free fraction of unconjugated bilirubin by using a new peroxidase-diazo assay. These investigators advocate the use of this assay and brainstem auditory evoked potential to improve the prediction of those jaundiced newborns at risk for neurotoxicity. As a cautionary note, it remains to be demonstrated if there exists a meaningful relationship between abnormal brainstem auditory evoked potential and permanent neurologic damage.

In this era of low prevalence of erythroblastosis fetalis, measurement of TSB remains invaluable in the management of infants with jaundice. Treating hyperbilirubinemia will likely prevent kernicterus in most instances. However, this also implies that we need to treat many jaundiced infants to prevent 1 from developing kernicterus. To illustrate, let us assume for the moment that the incidence of kernicterus is somewhere between 1 in 100 000 to 1 in 1 000 000 newborns and that 2% of the ~4 million newborns per year have TSB levels of ≥20 mg/dL. If we further assume that kernicterus only occurs with a TSB level of ≥20 mg/dL, then we will treat anywhere between 2000 and 20 000 newborns to prevent 1 case of kernicterus. TSB alone is a poor indicator of kernicterus risk. We need to explore the use of newer tools in conjunction with TSB to target infants at higher risk. Kernicterus is rare, but it is not extinct. As a preventable tragedy, it remains a highly controversial issue. Much work remains to be done to understand its pathophysiology and optimize its prevention.


    FOOTNOTES
 
Received for publication Jan 14, 2004; Accepted Jan 14, 2004.

Address correspondence to Stanley Ip, MD, Department of Pediatrics, Tufts-New England Medical Center, 750 Washington St, Box 63, Boston, MA 02111. E-mail: sip{at}0040tufts-nemc.org


    REFERENCES
 TOP
 REFERENCES
 

  1. Hsia D, Allen F, Cellis S, Diamond L. Erythroblastosis fetalis. VIII. Studies of serum bilirubin in relation to kernicterus. N Engl J Med. 1952;247 :668 –671
  2. Gupta AK, Mann SB. Is auditory brainstem response a bilirubin neurotoxicity marker? Am J Otolaryngol. 1998;19 :232 –236[CrossRef][Web of Science][Medline]
  3. Perlman M, Fainmesser P, Sohmer H, Tamari H, Wax Y, Pevsmer B. Auditory nerve-brainstem evoked responses in hyperbilirubinemic neonates. Pediatrics. 1983;72 :658 –664[Abstract/Free Full Text]
  4. Sabatino G, Verrotti A, Ramenghi LA, et al. Newborns with hyperbilirubinemia: usefulness of brain stem auditory response evaluation. Neurophysiol Clin. 1996;26 :363 –368[CrossRef][Web of Science][Medline]
  5. Tan KL, Skurr BA, Yip YY. Phototherapy and the brain-stem auditory evoked response in neonatal hyperbilirubinemia. J Pediatr. 1992;120(2 pt 1) :306 –308
  6. Vohr BR, Lester B, Rapisardi G, et al. Abnormal brain-stem function (brain-stem auditory evoked response) correlates with acoustic cry features in term infants with hyperbilirubinemia. J Pediatr. 1989;115 :303 –308[CrossRef][Web of Science][Medline]
  7. Vohr BR, Karp D, O’Dea C, et al. Behavioral changes correlated with brain-stem auditory evoked responses in term infants with moderate hyperbilirubinemia. J Pediatr. 1990;117(2 pt 1) :288 –291
  8. Ip S, Chung M, Kulig J, et al. Technical report: an evidence-based review of important issues concerning neonatal hyperbilirubinemia. Pediatrics. 2004;114(1) . Available at: www.pediatrics.org/cgi/content/full/114/1/e644
  9. Ostrow J, Pascolo L, Shapiro S, Tiribelli C. New concepts in bilirubin encephalopathy. Eur J Clin Invest. 2003;33 :988 –997[CrossRef][Web of Science][Medline]

PEDIATRICS (ISSN 1098-4275). ©2004 by the American Academy of Pediatrics

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
PediatricsHome page
A. F. McDonagh, H. J. Vreman, R. J. Wong, and D. K. Stevenson
Photoisomers: Obfuscating Factors in Clinical Peroxidase Measurements of Unbound Bilirubin?
Pediatrics, January 1, 2009; 123(1): 67 - 76.
[Abstract] [Full Text] [PDF]


Home page
Arch. Dis. Child.Home page
Journal Watch
Arch. Dis. Child., November 1, 2004; 89(11): 1074 - 1075.
[Full Text] [PDF]


Home page
PediatricsHome page
J. B. Worsley
Hyperbilirubinemia Guidelines and Unintended Harms
Pediatrics, October 1, 2004; 114(4): 1134 - 1135.
[Full Text] [PDF]


Home page
PediatricsHome page
N. A. Holtzman
Management of Hyperbilirubinemia: Quality of Evidence and Cost
Pediatrics, October 1, 2004; 114(4): 1086 - 1088.
[Full Text] [PDF]


Home page
JWatch PediatricsHome page
Hyperbilirubinemia: A Comprehensive New Guideline
Journal Watch Pediatrics and Adolescent Medicine, August 9, 2004; 2004(809): 3 - 3.
[Full Text]


This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ip, S.
Right arrow Articles by O’Brien, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ip, S.
Right arrow Articles by O’Brien, R.
Related Collections
Right arrow Office Practice
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?